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Abstract: Airway remodeling plays an important role in the devel-
opment of airway hyperresponsiveness in asthma. Muscarinic ago-
nists such as carbamylcholine increased cyclic GMP (cGMP) levels
in bovine tracheal smooth muscle strips, via stimulation of NO-
sensitive soluble guanylylcyclase (NO-sGC), which is an enzyme
highly expressed in the lungs. cGMP production, by activation of a
NO-sGC, may contribute to airway smooth muscle relaxation. To
determine whether the bronchoconstriction observed in asthma is
accompanied by changes in this NO-sGC activity, we used a
well-established murine model, ovalbumin-airway smooth muscle
cells (OVA-ASMCs) of allergic asthma to evaluate such hypothesis.
Histologic studies of trachea specimens showed the existence of
inflammation, hyperplasia and tissue remodeling in OVA-ASMCs.
Interestingly, cultured OVA-ASMCs showed lower GC basal activ-
ity than CONTROL-ASMCs. Also, we found that both OVA-
ASMCs and CONTROL cells exposed to carbamylcholine and
sodium nitroprusside and combinations of both drugs increased
cGMP levels, which were inhibited by 1H-[1,2,4]oxadiazolo[4,3-]
quinoxalin-1-one. All the experimental evidence suggests that NO-sGC
activity is reduced in isolated ASMCss from experimental asthma
murine model.
(WAO Journal 2010; 3:271–276)
Asthma is a chronic inflammatory disease that involves areversible obstruction of the airways.1 Asthma pathogen-
esis is characterized by the presence of the following factors:
(1) chronic inflammation, (2) airway hyperresponsiveness,
and (3) tissue remodeling. Furthermore, the remodeling pro-
cess is associated with the development of bronchial hyper-
reactivity. These elements together are responsible for revers-
ible obstruction of the airways and the clinical expression of
asthma.1–3
This chronic inflammatory process leads to structural
changes in the bronchial wall, involving hypertrophy and
hyperplasia of smooth muscle cells of airways (ASMCs)2–5 as
described above. The role of ASMCs in airway remodeling is
supported by increased muscle mass in the bronchial tree. In
this regard, there have been numerous morphometric studies
to test such an increase in muscle mass and to try to establish
the pathophysiologic mechanism, either hyperplasia (increase
in cell number) or hypertrophy (increase in cell volume) of
ASMCs.6–12
The cultured ASMCs under certain conditions may
develop different phenotypes. The “contractile phenotype”
has an intense staining for smooth muscle-specific contractile
proteins showing few organelles. By contrast, “synthetic
phenotype” exhibits increased mitogenic activity, and re-
duced staining for contractile proteins and more organelles
biosynthesis.13 Studies on phenotype modulation of smooth
muscle cells led to the hypothesis that the phenomenon of
“phenotypic plasticity” is not a simple artifact of cell culture
but rather the ASMCs “in vivo” express a certain range of
phenotypes. However, ASMCs either “in situ” or in culture
should not be considered exclusively contractile or synthetic,
but there is a balance between a heterogeneous population of
synthetic and contractile cells.13
NO is a bronchodilator and upregulation of its produc-
tion in the absence of other inflammatory stimuli decreases
airway resistance and responsiveness.14 However, the role of
NO in asthma is elusive, as it remains unclear whether the
excessive NO production associated with this disease is
protective or destructive for lung tissue. It is possible that
excessive NO lung production induces a downregulation of a
highly expressed soluble guanylyl cyclase (sGC) in lung,
which may occur in asthma.15 Previous reports have shown
that either in the lungs of asthmatic patients or in animal
models of asthma high levels of the enzyme inducible nitric
oxide synthase (iNOS) has been expressed.16 However, de-
spite the presence of large amounts of NO that could activate
sGC in smooth muscle and cause relaxation of the airways, it
does not occur in asthmatic patients. One possibility is to
determine whether the bronchoconstriction observed in
asthma is related to sGC changing activity, which may exist
in an allergic asthma model developed in murine (rats).
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MATERIALS AND METHODS
Ovalbumin-Induced Rat Model of Asthma
Female Sprague-Dawley rats were sensitized with in-
traperitoneal injections of 10 g of OVA (Sigma) plus 2 mg
of aluminum hydroxide (Pharmacy School, UCV, Venezu-
ela), as adjuvant, on days 0 and 5. From 7 to 14 days rats were
continually exposed by nebulizer (DeVilbiss Pulmo-Aide
model 5610D to an aerosol challenge containing either 0.9%
saline or 1% OVA for 30 min/d as described previously.17
Isolation and Culture of Airway Smooth
Muscle Cells
Primary cultures of rat ASMCs were established as
previously reported.18 Tracheas from rats were dissected in
ice-cold phosphate-buffered saline (PBS) solution, pH 7.4.
The epithelium was removed, and muscle layers were gently
separated from underlying connective tissue in small bundles,
which were placed in digestion solution containing 4 mg/mL
collagenase II (Worthington) and Dispase (GIBCO) for 60
minutes at 37°C and 5% CO2. The cell suspension was centri-
fuged at 500g for 15 minutes. Later, ASMCs were cultured in
Dulbecco’s modified Eagle’s medium/F-12 (DMEM/F-12;
GIBCO) supplemented with 10% fetal bovine serum (GIBCO),
1% L-glutamine, and 2% penicillin/streptomycin. These ASMCs
were characterized18 using immunofluorescence with the -actin
anti-smooth muscle monoclonal antibody (Sigma), being 100%
positive after the third passage. ASMCs between passages 3 and
7 were used for experiments.
Immunofluorescence Studies
The ASMCs in culture in cover slides were washed
with saline and treated with a fixative solution (2% parafor-
maldehyde and 1% sucrose in PBS, pH 7.4) for 30 minutes at
room temperature. Subsequently, the ASMCs were washed
with PBS, permeabilized with increasing concentrations of
methanol from 50% to 100% for 2 minutes at room temper-
ature. Later, the cells were incubated for 1 hour in a buffer
solution (PBS, 0.88% NaCl, and 2% bovine serum albumin)
to saturate nonspecific binding sites. The ASMCs were incu-
bated for 3 hours at 4°C with the primary antibody monoclo-
nal anti--actin (Sigma) and specific smooth muscle in a
dilution of 1:100 in PBS, 0.88% NaCl, and 2% albumin.
Furthermore, a washing step with the same buffer and a
second secondary antibody IgG (1:50 dilution) conjugated
rabbit anti-mouse-1-fluorescein isothiocynate (FITC) labeling
was performed by incubating for 30 minutes at room temper-
ature. Finally, immunolabeled cells were washed with PBS
for 20 minutes at room temperature. The fluorescence emitted
from labeled cells was visualized in a fluorescence micro-
scope (NiKon Labophot) at a magnification of 100 and
200 and photographic records were performed.
cGMP Production of ASMCs
The ASMCs were incubated for 15 minutes in the pres-
ence of IBMX (100 M). cGMP production was determined in
the presence of carbamylcholine (Cch, 1  105 M), sodium
nitroprusside (SNP, 100 M), and 1H-[1,2,4]oxadiazolo[4,3-
]quinoxalin-1-one (ODQ, 100 nM) for 5 minutes at 37°C. The
reaction was stopped by removing the medium immediately
and freezing with liquid N2, and later 500 L of 6% trichlo-
roacetic acid was mixed vigorously and the suspension was
centrifuged for 1500g  15 minutes. The acid supernatants
were extracted 2 times with ether saturated with water. Later,
the aqueous solutions were lyophilized and resuspended in
150 L of water. The cGMP produced was determined by
radioimmunoassay using the cGMP kit from Amersham, in
50 L of the supernatant, and the radioactivity [3H] was
measured by liquid scintillation spectrometry. Total protein
content of ASMCs was determined in the trichloroacetic acid
pellet, which was dissolved in a small amount of 1 N NaOH
and an aliquot was employed to estimate protein content,
using Lowry procedure.19 The amount of cGMP is expressed
in pmol/mg of total cellular protein.
Statistical Analysis
Data are mean  SEM. The statistical significance of
differences between means was determined by an unpaired
two-tailed Student t test. Differences were considered to be
significant (P  0.05).
RESULTS AND DISCUSSION
Histologic Evaluation of the Trachea of
Sprague-Dawley Rats (CONTROL and
Sensitized with OVA)
Histologic analyses confirmed the presence of inflam-
mation, a hyperplasia and hypertrophy of smooth muscle
tissue in the tracheas of OVA-sensitized rats as shown in
Figure 1. An interstitial edema of the lamina propia and
submucosa in the OVA group was observed. Also, an in-
crease in cell amount of the connective tissue in close
association with and hardly distinguishable from inflamma-
tory infiltrate cells was observed. The hyperplastic tissue was
located in the submucosa close to the perichondrial tissue.
Also, there were elongated smooth muscle cells with a ten-
dency to form bundles (Figs. 1C, D). Inflammatory cell
infiltrate being mainly mononuclear cells was present in
mucosa, submucosa, and smooth muscle (Figs. 1C, D). An-
giogenesis was present in the lamina propria and submucosa,
which were not observed in CONTROL rats’ trachea (Fig. 1).
Thickness of the adventitia is due to greater deposition of
extracellular matrix (Fig. 1). Finally, the structure of the
tunica tracheal cartilage of the OVA-rats group showed no
difference with respect to CONTROL.
The histologic findings of the CONTROL rats’ trachea
compared with OVA rats indicate that OVA sensitization
triggered an inflammatory process, which was associated
with the remodeling of the tracheal wall, which is similar to
ones that have been described in patients with human asth-
ma.2–5 In summary, in our murine (rat) model, tissue remod-
eling was present in all regions of the tracheal wall and was
characterized by hyperplasia and denudation of the epithelial
layer, subepithelial fibrosis, angiogenesis, and thickness of all
layers. Interestingly, in OVA samples a mononuclear cell
infiltrate was found in the mesenchymal tissue cells and
smooth muscle cells.
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Immunofluorescence Studies
The characterization of culture smooth muscle cells
was performed by indirect immunofluorescence. The specific
anti--actin antibodies immunolabeling was performed in
primary cultures, revealing that 100% were positive for
smooth muscle cells in both the OVA and CONTROL
groups, though passages 3 and 5 (Fig. 2) showed long,
straight, uninterrupted fibrils densely arranged along its lon-
gitudinal axis. The nucleus and the cytoplasm located be-
tween the myofilaments were not labeled.20,21
Consequently, the cells being positive with anti--
smooth muscle actin indicates that isolated cells from all
tracheas (OVA and CONTROL groups) correspond to
ASMCs and not another cell type. In addition, our cultured
ASMCs exhibited the classic modulation processes (transi-
tion to the synthetic-proliferative phenotype) and maturation
(transition to the contractile phenotype) described in previous
studies.13,22–24 These results argue against the ASMC mor-
phology heterogeneity described in primary cultures, which
was explained by 2 different isolated cell types, or the
presence of 2 phenotypes of smooth muscle cells, such as
described elsewhere.20,21
Interestingly, our primary cultures obtained from OVA
group rats are composed of cells, exhibiting an ASMC syn-
thetic-proliferative phenotype with an increment in density or
confluence monolayer, giving the appearance of less orga-
nized culture compared with the CONTROL group.
cGMP Production in Cultured ASMCs
Previous evidences suggest that excessive NO produc-
tion induces a downregulation of NO-sensitive guanylyl cy-
clase (sGC), which may occur in asthma.15 Following this
rationale, we investigated the cGMP production in airway
smooth muscle cultured cells in the presence of sGC-selective
activators (SNP, a donor of NO) and a selective sGC inhibitor
(ODQ). In addition, muscarinic agents such as Cch have been
shown to increase the cGMP levels in intact tracheal smooth
muscle strips, via sGC activation25 and membrane-bound
guanylylcyclases,26 which was also evaluated in our cell
culture assays.
Thus, the sGC activity was determined, in cultured
ASMCs, preincubated for 15 minutes with 100 M IBMX (a
powerful inhibitor of cyclic nucleotide phosphodiesterase).
Thus, the GC activity was estimated indirectly by the pro-
duction of cGMP in the presence of 100 M SNP and 1 
105 M Cch and the combination of both agents. Thus, in
ASMC CONTROL group (n  5), the basal activity was
stimulated 2.6 times by SNP, being increased 1.6 times
with Cch and further potentiated synergistically (4.2 times)
in the combination of Cch and SNP. To establish the sGC
role, a classic inhibitor of this NO-sensitive GC as ODQ was
tested in all assay conditions. Thus, in CONTROL ASMCs,
100 nM ODQ inhibited the basal activity 70%, the SNP
stimulation was decreased in 55%, and the Cch stimulation
was decreased in 28%. All these data suggest that sGC was
FIGURE 1. Airway smooth muscle histologic studies from OVA-sensitized and control rats. The panels (A) and (B) represent
the typical tracheal tissue of the CONTROL rats group showing a thin layer of smooth muscle (SMt) located between the
edges of the hyaline cartilage ring (HC) and it is enclosed by connective tissue (CT) with the adventitia. The SM is bound to
perichondrial tissue (p) through bundles of smooth muscle cells (SMC). These SMC cells have elongated shape, eosinophilic
cytoplasm, and basophilic nucleus. The panels (C) and (D) represent the tracheal wall of OVA rats, having a characteristic lay-
ered arrangement of the trachea, because the epithelium (Hep) is thickened with hyperplasia of caliciform cells (mL), basal
membrane (Bm), lamina propia (LP), and tunic submucosa (SM). Increased cellular connective tissue and mononuclear cell
infiltration (*), and formation of blood vessels (BV), are shown. In the layer of SM an inflammatory infiltrate around the SMC
is also observed. Sections were stained with hematoxylin & eosin. Magnification: 100 (A,C) and 400 (B, D).
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involved in such cGMP production. Interestingly, in OVA-
ASMCs (n  5) showed lower GC basal activity compared
with CONTROL ASMCs (P  0.05). In this sense, the fold
stimulations induced by SNP (9 times) and Cch (7 times) and
SNP  Cch (14 times) were higher in OVA-ASMCs than in
CONTROL ASMCs, all being inhibited by ODQ in 70%.
These results are shown in Figure 3.
Our results showed that NO-sensitive sGC activity is
decreased in ASMCs from a well-established murine model
of allergic asthma associated with rat sensitized and chal-
lenged with OVA. Our results in OVA-ASMCs support the
experimental findings in intact lung tissue from OVA-sensitized
mice described by Papapetropoulos et al.15 These authors de-
scribed in a experimental asthma murine model a substantial
decrease between 60% and 80% in the steady-state levels of
sGC subunit mRNA from lung tissue using real-time PCR. In
addition, these changes in mRNA were paralleled by changes at
the protein level expression, which was reduced by 50%–80%
as determined by Western blotting.15
Interestingly, our experimental results indicate that
OVA-ASMCs retained the cell phenotype that exists in the
intact murine lungs, demonstrating that our findings about the
FIGURE 2. Characterization of
airway smooth muscle cells by
-actin smooth muscle immu-
nofluorescence: Specific pri-
mary antibody against -actin
(1:100) and FITC-conjugated
secondary antibody (1:50)
were used. Panels (C, OVA)
and (A, CONTROL) represent
the typical photography
records of cells culture under
fluorescence microscope. Panels
(D, OVA) and (B, CONTROL)
are phase-contrast microscopy
records. Magnification: 200.
Bar  150 m. The immunola-
beling was performed in ASMCs
from different trachae from OVA
and CONTROL rats (n  3) for
each experimental condition.
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reduced sGC is not an artifact or an induced response of cultured
ASMCs due to the tissue culture conditions. In addition, this
experimental finding supports the use of this murine model for
future studies in allergic asthma. At this moment, we do not have
evidence to define the type of phenotype (“contractile” or “syn-
thetic”) displayed by our ASMCs responsible for these biologic
responses. However, ASMCs either “in situ” or in culture should
not be considered exclusively contractile or synthetic, but rather
as a balance between a heterogeneous population of synthetic
and contractile cells.13
Interestingly, the NO-cGMP-dependent protein kinase
cascade has been implicated in the regulation of the mitogen
activated protein kinase (MAPK) system.27,28 Thus, the decre-
ment in this cyclic nucleotide cascade activity induces the
activation of the MAPK kinases leading to cell division, which
is associated with the hyperplasia of airway smooth muscle.28
It is possible that a long-term downregulation of sGC in
asthma may contribute to the increased airway reactivity to
bronchoconstrictors and might also be implicated in the
hyperplastic smooth muscle responses and remodeling that
occurs in this lung disease.
CONCLUSIONS
We found that all ASMCs exposed to a NO-donor com-
pound as SNP and muscarinic agonist as carbamylcholine in-
creased cGMP intracellular levels, which were inhibited by
ODQ, suggesting that sGC is the main guanylyl cyclase enzyme
responsible for cGMP production in these ASMCs. However,
OVA-ASMCs showed low basal cGMP production compared
with CONTROL ASMCs possibly because of reduced sGC
expression. It is important to emphasize that the cGMP degra-
dation was inhibited by the use of IBMX. In addition, SNP and
Cch stimulation in OVA-ASMCs were higher than CONTROL
ASMCs. Both these cGMP-dependent SNP and Cch increments
in OVA-sensitive ASMCs were inhibited to ODQ.
We concluded that the ASMCs from OVA-sensitized
rats display morphologic and proliferative characteristics dif-
ferent from the CONTROL as similar to ones described
elsewhere in intact OVA-sensitized murine lungs.15 Thus,
both of the sGC activities expressed as the cGMP cell content
were reduced in the experimental asthma model, which may
contribute to airway hyperreactivity present in asthma.
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